Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific reporting date of October 12, 2021. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Transaction Type | Instrument | Price per Share | Total Volume per Individual |
|---|---|---|---|
| Acquisition under Share Reward Plan | Ordinary Shares (25 pence each) | £13.9739 | 18 Shares (9 partnership + 9 matching) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine compliance disclosures for executive share acquisitions executed on October 11, 2021, on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Date: All reported transactions occurred on October 11, 2021.
- Participants: Acquisitions were made by 11 individuals, including CEO Emma Walmsley, President of Vaccines & Global Health Richard Connor, and CEO of ViiV Healthcare Daria Waterhouse.
- Transaction Nature: All transactions were acquisitions of Ordinary Shares via the Company's Share Reward Plan, consisting of partnership and matching shares.
- Volume: Each individual acquired a total of 18 shares at a uniform price of £13.9739.
- Market: Transactions were executed on the London Stock Exchange (XLON).